Lisa Rosenbaum, M.D.: Transitional Enduring or Chaos Harm? The EHR and the Disruption of Medicine A decade ago, a primary care physician We admired seemed to come undone. His efficiency had derived not from rushing between sufferers but from knowing them so well that his charting was effortless and fast. But he became distracted suddenly, losing his hold on the details of his individuals’ lives. He slumped around, shirt half-untucked, perpetually pulling a yellowed handkerchief from his pocket to clean his perspiring forehead.Robert Mutter, MD, of the Mayo Clinic in Rochester, Minnesota. Dr. Mutter will study comprehensively characterized chemoresistant triple harmful breast cancer xenograft models established from individuals with high risk breast cancers in a preoperative chemotherapy medical trial. He will investigate if chemoresistance predicts test and radioresistance new DNA fix strategies aimed at overcoming resistance. Related StoriesSTA inks license and commercialisation agreement with PharmaMar for APLIDIN Most cancer patients lack access to safe, affordable surgical careMirati to provide data on tyrosine kinase inhibitor at ESMO 2015 European Malignancy CongressThe ASTRO Occupants/Fellows in Radiation Oncology Study Seed Grant awards $25,000 for one-year projects to occupants and fellows who are preparing to pursue careers concentrating on basic science or clinical study in radiation oncology solutions.